Diverse Biotech Medical Team

Our Inventors

Lead Science | Experienced With Proven Track Record

Paul Hershberger, PhD

Chief Chemist

Philip Arlen, PhD

Chief Scientific Officer

Our Medical Team

Medical Scientific | World-Renowned Advisory Board

Henry S. Friedman, MD

duke university medical center
Dr. Friedman world’s foremost expert in glioblastomas. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University.

Joyce Ann O’Shaughnessy, MD

Texas Oncology & US Oncology Research
Dr. O’Shaughnessy one of the top three experts in breast cancer in the UNITED STATES. Dr. O’Shaughnessy focuses on breast cancer prevention and treatment. She is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The US Oncology Network and is a member of the Scientific Advisory Board for US Oncology Research Network.

Armand B. Cognetta Jr, MD

Florida State University
Dr. Cognetta one of the nation’s leading dermatologists. Dr. Cognetta is founder and president of Dermatology Associates of Tallahassee. He started practicing under the Dermatology Associates namesake in June 1985. He received his medical degree from the University of Connecticut Medical School in 1979, served his residency at Tallahassee Memorial Hospital, and served his dermatology residency at the University of Alabama in Birmingham. Dr. Cognetta also served his MOHs Fellowship at the University of Alabama in Birmingham. Dr. Cognetta is an associate professor of dermatology at the Florida State University School of Medicine. Dr. Cognetta is also a Clinical professor and Chief of the Division of Dermatology for the FSU College of Medicine. He is also a fellowship director at the American College of MOHs Micrographic Surgery and Cutaneous Oncology. Dr. Cognetta is widely published and lectures on early detection of melanoma and skin cancer management. He also currently trains one Fellow a year for the American College of MOHs Micrographic Surgery and Cutaneous Oncology. Dr. Cognetta and his staff currently specialize in the early detection and treatment of skin cancer.

David Ashley, MD, PhD

Duke University Medical Center
Dr. Ashley one of the global experts in pediatric neuro-oncology. Dr. Ashley’s career in cancer research dates more than two decades. He is credentialed in both pediatric and adult neuro-oncology practice and this has been the focus of my efforts in translational research and leadership. As evident from his publication and grant support record, his primary academic focus has been on neurologic tumors, the development of innovative therapies and approaches to care. These efforts have included basic and translational laboratory research. His experience includes moving laboratory findings in brain tumor immunology and epigenetics into early phase clinical trials. He has expertise in immuno-oncology, having developed and clinically tested dendritic cell vaccines and other immuno-therapeutics. His achievements in research have led to change in practice in the care of children and adults with brain tumors, including the introduction of new standards of practice for the delivery of systemic therapy. He is highly regarded for this work, as evidenced by numerous invitations to plenary sessions and symposia of international standing. He has been the principal investigator of a number of important national and international studies, both clinical and pre-clinical. He is recognized as a senior figure and opinion leader in neuro-oncology nationally and internationally. He has held several significant leadership roles, including Director of two major cancer centers, and served as the Chair of Medicine at Deakin University, the Program Director of Cancer Services at University Hospital Barwon Health, and Executive Director of the Western Alliance Academic Health Science Centre (Australia). He began his current position as Director of The Preston Robert Tisch Brain Tumor Center, Head, Preuss Laboratory, in March 2018. In this role, he is responsible for the clinical care, research, and educational program related to Brain Tumor Center. He is also a senior investigational neuro-oncologist within the adult brain tumor program at Duke.

Douglas Heldreth, MD

Florida Cancer Specialists
Dr. Douglas Heldreth is a board-certified oncologist for Florida Cancer Specialists & Research Institute. Dr. Heldreth received his medical degree from West Virginia University School of Medicine in Morgantown, WV. He completed an internship in Internal Medicine at Charleston Area Medical Center in Charlestown, WV and a residency in Internal Medicine at Orlando Regional Medical Center/University of Florida. Dr. Heldreth gained additional training through a fellowship in Medical Oncology at the University of South Florida College of Medicine in Tampa and frequently serves as a sub-investigator for Phase 1, 2 and 3 clinical trial research studies.

Neal D. Shore, MD, FACS

Director, CPI, Carolina Urologic Research Center
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21 st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6- month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan- Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

Dr. John Patrick, MD

Virginia Commonwealth University
Dr. John Patrick is our Executive Vice President and earned his MD from the Medical College of Virginia, now Virginia Commonwealth University. He is a board certified and practicing anesthesiologist who is also an active high-level entrepreneur. Dr. John is our Chief Medical Officer and Chairman of the Medical Committee, directing and consulting with national experts for our upcoming clinical trials. He is also an active member of the Board of Directors of Diverse Biotech, assisting in expanding the Company's intellectual property and has been instrumental in driving the Company's capital raises.

Michael Vaughn, MD, PhD.

Medical College of Virginia/ VCU
Michael P. Vaughn, MD, PhD is our Director of Clinical Development. Dr. Vaughn had his PhD training at the Department of Microbiology and Immunology at the Medical College of Virginia/ VCU and was sponsored by an NIH training grant. His laboratory experience in Transplant and Cancer Immunology began even prior to his Medical training. Dr. Vaughn is Board Certified in Internal Medicine, Emergency Medicine and Allergy, & Immunology (A&I). He currently practices part-time in A&I and in 2023 was selected by his peers as one of San Antonio’s “Best Doctors” in his field of practice.

William Fisher, MBA

Wharton Business School
William Fisher, founder of Diverse Biotech, is revolutionizing cancer treatment through groundbreaking drug discovery. Building upon a scientific background he has gained and developed through extensive business operations, he assembled a world-class team of respected doctors and scientists, leading the charge in inventing a novel class of drugs that has shown promising results in preclinical trials. A risk-taker and thrill-seeker, William's pursuits extend beyond the boardroom to motorcycle racing, offshore fishing, and piloting aircraft. His visionary leadership has propelled Diverse Biotech to the forefront of transformative cancer therapies.

Our Discovery

Diverse Biotech Innovation & Medical Discovery

Diverse Biotech, Inc., is not a “single-drug” or “single-disease” company.

Learn More